Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia
This phase 2b trial of a short interfering RNA that targets APOC3 showed substantive dose-dependent lowering of triglyceride levels.
The New England Journal of Medicine:...
Autoantibodies Targeting Nephrin in Podocytopathies
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Toward a Tobacco-free Generation — A Birth Date–Based Phaseout Approach
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
Red-Cell Rosette Formation in Malaria
New England Journal of Medicine, Ahead of Print.
massmed: New England Journal of Medicine: Table of Contents
